Back to top
more

Kymera Therapeutics (KYMR)

(Delayed Data from NSDQ)

$35.12 USD

35.12
619,727

+1.36 (4.03%)

Updated Apr 18, 2024 03:59 PM ET

After-Market: $35.13 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KYMR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Kymera Therapeutics, Inc. [KYMR]

Reports for Purchase

Showing records 1 - 20 ( 31 total )

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/23/2024

Company Report

Pages: 7

Kymera’s KT-294 (TYK-2 Degrader) Continues to Build a Differentiated Narrative; Reiterate Buy and PT Up to $46

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/23/2024

Company Report

Pages: 7

Kymera’s KT-293 (TYK-2 Degrader) Continues to Build a Differentiated Narrative

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/05/2024

Company Report

Pages: 5

Newly Unveiled Immunology Programs Attractive for Potential Partnership Deals

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/12/2023

Daily Note

Pages: 3

PK, PD, and Safety Data Allow Wider Therapeutic Window for KT-333; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KYMR 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/03/2023

Company Report

Pages: 7

Initial PoC Data From STAT3 and MDM2 Programs Supports Further Development; Reiterate Buy and PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/04/2023

Company Report

Pages: 7

KT-253’s Superiority to SMIs Supports Degrader Approach to Target MDM2; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/08/2023

Company Report

Pages: 7

Expectations for KT-413’s ICML Data Readout; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

03/13/2023

Industry Report

Pages: 5

KOL Call Invite: Getting Under the Skin in HS & PsA

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 5.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

02/24/2023

Company Report

Pages: 7

KT-253 is an Ambitious Program with Potential for Broad Franchise Opportunities; Reit. Buy and $85 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

12/15/2022

Daily Note

Pages: 4

Sanofi Puts Skin in the Game¯Thoughts on KT-474 Data Readout

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/14/2022

Industry Report

Pages: 4

Cereblon Dumps Thalidomide for Better Degrons¯Takeaways From The 5th Targeted Protein Degradation Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/04/2022

Company Report

Pages: 7

KT-333¯Drugging the Undruggable STAT3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/30/2022

Company Report

Pages: 4

EADV Data Stresses the Importance of Scaffolding Function of IRAK4, Pending Biomarker Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/10/2022

Company Report

Pages: 7

Setting Appropriate Expectations for KT-474’s Part C Study; Reiterate Buy and $85 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/04/2022

Company Report

Pages: 7

Considerations for Kymera’s KT-474 Patient Study Readout in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

04/11/2022

Daily Note

Pages: 4

MDM2 Degrader KT-253 Open Broad Franchise Opportunities For Kymera - Our Thoughts on AACR Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

02/28/2022

Company Report

Pages: 7

KT-474''s Proof of Biology Data in 2H22 Is All About Safety and Cytokine Suppression

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

12/17/2021

Daily Note

Pages: 6

KT-474 Data Places Kymera as a TPD Leader in the Inflammatory Disease Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kymera Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/15/2021

Daily Note

Pages: 4

STAT3 Degradation in Combination with anti-PD1 Therapy is a Promising Strategy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party